--- type: "Symbol" title: "MicuRx (688373.SH) — Community Discussions" description: "Community discussions about this stock, including analyst opinions, earnings analysis, and investment strategies from verified financial professionals and active investors." locale: "en" url: "https://longbridge.com/en/quote/688373.SH/topics.md" symbol: "688373.SH" parent: "https://longbridge.com/en/quote/688373.SH.md" count: 10 datetime: "2026-03-13T07:34:46.303Z" locales: - [en](https://longbridge.com/en/quote/688373.SH/topics.md) - [zh-CN](https://longbridge.com/zh-CN/quote/688373.SH/topics.md) - [zh-HK](https://longbridge.com/zh-HK/quote/688373.SH/topics.md) --- # MicuRx (688373.SH) — Community Discussions ### [燧原科技科创板 IPO 获受理 "国产 GPU 四小龙"齐聚资本市场](https://longbridge.com/en/topics/37965685.md) - Author: [财见caijian](https://longbridge.com/en/profiles/13190262.md) - Datetime: 2026-01-21T02:45:55.000Z - Comments: 0 - 2025 年末，随着摩尔线程、沐曦股份在科创板上市后股价表现强劲，及 2026 年初壁仞科技成功登陆港股，国产高端 GPU 领军企业集群加速对接资本市场。如今，"国产 GPU 四小龙"阵营的最后一块关键拼图即将就位 —— 上海燧原科技股份有限公司的科创板 IPO 申请已于 1 月 22 日获证监会受理，标志着其上市进程进入冲刺阶段，这家估值达 205 亿元的独角兽企业有望在二级市场 ### [Mengkopharma has once again been recognized as a high-tech enterprise](https://longbridge.com/en/topics/37965548.md) - Author: [财见caijian](https://longbridge.com/en/profiles/13190262.md) - Datetime: 2026-01-21T02:43:24.000Z - Comments: 0 - Recently, the Office of the Leading Group for the Management of National High-tech Enterprise Certification issued the "Announcement on the Filing of the First Batch of High-tech Enterprises Repor ### [Deepen professional communication, practice responsible communication ---- Two cases of MicuRx Pharmaceuticals won the "White Jade Cong Demonstration Case" award](https://longbridge.com/en/topics/37965511.md) - Author: [财见caijian](https://longbridge.com/en/profiles/13190262.md) - Datetime: 2026-01-21T02:42:28.000Z - Comments: 0 - Recently, the 12th "White Jade Cong Cup" (Shanghai) Excellent Public Relations Case Selection Event, hosted by the Shanghai Public Relations Association, came to a successful conclusion. Two c ### [Youxita® successfully renewed the new version of the drug catalog](https://longbridge.com/en/topics/37050289.md) - Author: [财见caijian](https://longbridge.com/en/profiles/13190262.md) - Datetime: 2025-12-11T01:44:27.000Z - Comments: 0 - On December 7, 2025, according to the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2025)" (hereinafter referred to as the "New Drug List" ### [Shanghai MicuRx Pharmaceutical Co., Ltd. and ProBioGen AG have reached a strategic cooperation for the joint development of ADC drugs](https://longbridge.com/en/topics/34589584.md) - Author: [财见caijian](https://longbridge.com/en/profiles/13190262.md) - Datetime: 2025-09-29T03:15:00.000Z - Comments: 0 - Recently, Shanghai MediciNova Pharmaceutical Co., Ltd. (hereinafter referred to as "MediciNova",$MicuRx(688373.CN)) and Nanjing Prosperous Biotechnology Co., Ltd. (hereinafter referred to as & ### [Mengkang Pharmaceutical sells controlling stake for over 1 billion yuan: Debt-to-asset ratio reaches 59.45%, can they really get ashore by hitching a ride with 'Whale'?](https://longbridge.com/en/topics/34425000.md) - Author: [医药研究社](https://longbridge.com/en/profiles/15545088.md) - Datetime: 2025-09-24T13:13:55.000Z - Comments: 0 - Selling oneself to survive, burning one's boats—did Menko Pharmaceutical bet right? On September 22, Menko Pharmaceutical announced that the company plans to issue 163,901,373 shares to Nanjing Haijin ### [Achieved revenue of 130 million yuan in 2024, with multiple milestones in the R&D pipeline.](https://longbridge.com/en/topics/29246951.md) - Author: [财见caijian](https://longbridge.com/en/profiles/13190262.md) - Datetime: 2025-04-30T03:41:06.000Z - Comments: 0 - On March 17, 2025, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx"$MicuRx(688373.CN)) released its 2024 annual report. In 2024, the company achieved operating revenue of 130 million yuan, a ### [The anti-NTM infection new drug MRX-5 independently developed by MicuRx Pharmaceuticals has received FDA orphan drug designation.](https://longbridge.com/en/topics/26385213.md) - Author: [财见caijian](https://longbridge.com/en/profiles/13190262.md) - Datetime: 2025-01-02T02:20:38.000Z - Comments: 0 - On December 23, 2024, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx",$MicuRx(688373.CN)) received orphan drug designation from the FDA for its self-developed anti-infective new drug MRX-5, ### [MicuRx Pharmaceuticals: Successfully completed Phase III clinical trial of MRX-4 for Injection in China](https://longbridge.com/en/topics/25799905.md) - Author: [财见caijian](https://longbridge.com/en/profiles/13190262.md) - Datetime: 2024-11-29T07:08:33.000Z - Comments: 0 - Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx",$MicuRx(688373.CN)) has successfully completed the Phase III clinical trial in China for the treatment of adult patients with compl ### [MicuRx Pharmaceuticals: Q1 2024 revenue reached approximately 33.02 million yuan, a year-on-year increase of 91.10%.](https://longbridge.com/en/topics/20783978.md) - Author: [财见caijian](https://longbridge.com/en/profiles/13190262.md) - Datetime: 2024-04-28T04:01:22.000Z - Comments: 0 - On the evening of April 25, the company released its Q1 2024 report. During the reporting period, the company achieved operating revenue of 33.0161 million yuan, a year-on-year increase of 91.10%; net ## References - [MicuRx (688373.SH)](https://longbridge.com/en/quote/688373.SH.md) > Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/688373.SH/topics.md) | [繁體中文](https://longbridge.com/zh-HK/quote/688373.SH/topics.md)